These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24522743)

  • 1. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
    Okuyama A; Nakamura F; Higashi T
    Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
    Okuyama A; Nakamura F; Higashi T
    JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
    Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
    Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.
    Mahendraratnam N; Farley JF; Basch E; Proctor A; Wheeler SB; Dusetzina SB
    Support Care Cancer; 2019 Dec; 27(12):4525-4534. PubMed ID: 30915567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certified nurse specialists in cancer nursing and prophylactic antiemetic prescription for chemotherapy patients.
    Okuyama A; Takemura Y; Sasaki M; Goto A
    Support Care Cancer; 2022 Jul; 30(7):5931-5937. PubMed ID: 35391572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
    Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
    Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study.
    Yaguchi-Saito A; Kaji Y; Matsuoka A; Okuyama A; Fujimori M; Saito J; Odawara M; Otsuki A; Uchitomi Y; Zenda S; Shimazu T
    BMJ Open; 2022 Jun; 12(6):e055473. PubMed ID: 35667723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network.
    Hori K; Kobayashi N; Atsumi H; Nagayama A; Kondoh M; Noge I; Kimura M; Utsugi H; Iwasaki T; Nakamura M; Kimura T
    Support Care Cancer; 2014 Apr; 22(4):969-77. PubMed ID: 24276954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
    Chan A; Low XH; Yap KY
    J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations.
    Encinosa W; Davidoff AJ
    JAMA Oncol; 2017 Mar; 3(3):320-326. PubMed ID: 27632203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database.
    Okuyama A; Boku N; Higashi T
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1482. PubMed ID: 34176233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
    Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H
    Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.
    Ann Oncol; 1998 Jul; 9(7):759-65. PubMed ID: 9739443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
    Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
    Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.